Abstract: The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.

Abstract: The present invention discloses compounds of formula (I) or (II), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit, preventing or treating abnormal cellular proliferation and/or a viral infection, particularly by HIV, HCV or HBV. Consequently, the compounds of the present invention interfere with the replication cycle of a virus and are also useful as antiviral agents, or interfere with host cellular biochemical process and are also useful as antiproliferative agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from viral infection and/or cell proliferation. The invention also relates to methods of treating a viral infection and/or cell proliferation in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of Formulae (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing viruses, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.

Abstract: The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.

Abstract: The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.

Abstract: This invention relates to a clothes hanger comprising a hanging rod and a linkage mechanism. The hanging rod comprises a hanging unit and a guiding rod with its upper end connected to the hanging unit. The linkage mechanism comprises a sliding unit, a first linkage arm, and a second linkage arm. The sliding unit is affixed in an up-down slidable manner to the guiding rod. The first linkage arm is installed at a left side of the guiding rod, and the first linkage arm has a first end connected to the sliding unit and a second end connected to a lower end of the guiding rod. The second linkage arm is installed at a right side of the guiding rod, and the second linkage arm has a first end connected to the sliding unit and a second end connected to the lower end of the guiding rod.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.

Abstract: The present invention discloses compounds of Formulae (I) and (II), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.

Abstract: A data analysis method for an integrated circuit process is described, for analyzing the results of at least an in-line quality test, a product test and a yield test done to the products of the IC process. The products are divided into a normal group and an abnormal group based on the result of the in-line quality test, and are divided into a qualified group and an unqualified group based on the result of the yield test. A categorization step is performed to define the intersection of the unqualified group and the normal group as a first problematic group and to define the intersection of the unqualified group and the abnormal group as a second problematic group. By analyzing one or both of the two problematic groups, the major yield killer can be identified so that process modification can be made accordingly to improve the yield.

Abstract: A data analysis method for an integrated circuit process is described, for analyzing the results of at least an in-line quality test, a product test and a yield test done to the products of the IC process. The products are divided into a normal group and an abnormal group based on the result of the in-line quality test, and are divided into a qualified group and an unqualified group based on the result of the yield test. A categorization step is performed to define the intersection of the unqualified group and the normal group as a first problematic group and to define the intersection of the unqualified group and the abnormal group as a second problematic group. By analyzing one or both of the two problematic groups, the major yield killer can be identified so that process modification can be made accordingly to improve the yield.

Abstract: An abdominal exercise device for exercising the stomach while seated includes a first frame portion for abutting against an upper surface of the legs of a person and includes an elongated rear member, an elongated front member and a pair of elongated side members attached together. A second frame portion for abutting against the torso includes a pair of legs and an elongated central member attached together such that the second frame portion generally has a U-shape. Each of a pair of coupling members pivotally couples free ends of the pair of legs to the first frame portion at junctures of the rear member and the pair of side members. A pair of biasing members biases the central portion away from the front member such that the first frame portion lies in a plane orientated perpendicular to a plane of the second frame portion.

Abstract: An abdominal exercise device for exercising the stomach while seated includes a first frame portion for abutting against an upper surface of the legs of a person and includes an elongated rear member, an elongated front member and a pair of elongated side members attached together. A second frame portion for abutting against the torso includes a pair of legs and an elongated central member attached together such that the second frame portion generally has a U-shape. Each of a pair of coupling members pivotally couples free ends of the pair of legs to the first frame portion at junctures of the rear member and the pair of side members. A pair of biasing members biases the central portion away from the front member such that the first frame portion lies in a plane orientated perpendicular to a plane of the second frame portion.

Abstract: Ionic gel polymer electrolytes for rechargeable polymer batteries preferably are formed by dissolving a gelling agent into organic liquid electrolytes, and then gelling the precursor in situ at elevated temperature after pouring it into a battery case that contains a cathode, an anode and a separator. The gel polymer electrolytes exhibit excellent ionic conductivity of up to about 10?2 S/cm and voltage stability for lithium rechargeable batteries. Most preferably, the gel polymer electrolyte is the reaction product of (A) a heterocyclic amine-group containing material (preferably a vinvlpyridine), and (B) halide or epoxy-group containing polymers, copolymers, oligomers or monomers that are capable of reacting with nitrogen-containing compounds, such as polymers, copolymers, oligomers or monomers containing alkylene halides or halomethyl group substituted aromatic units or at least one epoxy unit.

Abstract: Lithium-ion electrochemical cells include an anode, a cathode and a separator between the anode and cathode, wherein at least one of the anode, cathode and separator includes a polysiloxane coating thereon. Most preferably, the polysiloxane coating is the polymerized reaction product of dimethyl siloxane and tetra(trimethylsiloxy) silane), and is present on the surface in an amount between about 0.05 to about 0.17 mg/cm2. After being coated with the polysiloxane adhesive, the electrodes and separator can easily be attached one to another at ambient temperature by application of pressure using a hand roller or with a laminator, and then subsequently formed into a spiral or stacked structure for placement in a battery cell case.

Abstract: Ionic gel polymer electrolytes for rechargeable polymer batteries. In preferred forms, a gel polymer precursor electrolyte is formed by dissolving a gelling agent into organic liquid electrolytes, and then gelling the precursor in situ at elevated temperature after pouring it into a battery case that contains a cathode, an anode and a separator. The gel polymer electrolytes exhibit excellent ionic conductivity of up to about 10−2 S/cm and voltage stability for lithium rechargeable batteries.

Abstract: Ionic gel polymer electrolytes for rechargeable polymer batteries. In preferred forms, a gel polymer precursor electrolyte is formed by dissolving a gelling agent into organic liquid electrolytes, and then gelling the precursor in situ at elevated temperature after pouring it into a battery case that contains a cathode, an anode and a separator. The gel polymer electrolytes exhibit excellent ionic conductivity of up to about 10−2 S/cm and voltage stability for lithium rechargeable batteries.

Abstract: Lithium-ion electrochemical cells include an anode, a cathode and a separator between the anode and cathode, wherein at least one of the anode, cathode and separator includes a polysiloxane coating thereon. Most preferably, the polysiloxane coating is the polymerized reaction product of dimethyl siloxane and tetra(trimethylsiloxy) silane), and is present on the surface in an amount between about 0.05 to about 0.17 mg/cm2. After being coated with the polysiloxane adhesive, the electrodes and separator can easily be attached one to another at ambient temperature by application of pressure using a hand roller or with a laminator, and then subsequently formed into a spiral or stacked structure for placement in a battery cell case.